EMA/834945/2022

European Medicines Agency decision

P/0453/2022

of 24 October 2022

on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (Voxzogo), (EMEA-002033-PIP01-16-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0453/2022

of 24 October 2022

on the acceptance of a modification of an agreed paediatric investigation plan for vosoritide (Voxzogo), (EMEA-002033-PIP01-16-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0379/2017 issued on 19 December 2017, decision P/0060/2020 issued on 10 February 2020 and decision P/0051/2022 issued on 11 March 2022,

Having regard to the application submitted by BioMarin International Limited on 29 September 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for vosoritide (Voxzogo), powder for solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BioMarin International Limited, Shanbally, Ringaskiddy, P43 R298 - Cork, Ireland.

EMA/PDCO/798469/2022
Amsterdam, 14 October 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002033-PIP01-16-M03

Scope of the application

Active substance(s):

Vosoritide

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of achondroplasia

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

BioMarin International Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BioMarin International Limited submitted to the European Medicines Agency on 29 September 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0379/2017 issued on 19 December 2017, decision P/0060/2020 issued on 10 February 2020 and decision P/0051/2022 issued on 11 March 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 3 October 2022.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition

Treatment of achondroplasia

2.1.1. Indication(s) targeted by the PIP

Treatment of achondroplasia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	**Study 1** Bio-distribution study in rat (BMN111-17-027)
Clinical studies	**Study 2** Open-label, sequential cohort dose-escalation study to evaluate the safety, efficacy and pharmacokinetics of vosoritide (BMN 111) in children with achondroplasia (111-202) **Study 3** Open-label extension study to evaluate the long-term safety, tolerability, and efficacy of BMN 111 in children with achondroplasia (111-205) **Study 4** Randomised, placebo-controlled, double-blind multicentre study to evaluate the efficacy, safety and tolerability of BMN 111 versus placebo in children from 5 to less than 18 years of age with achondroplasia (111-301)

	Study 5 Multicentre, multinational study to collect specific growth measurements on paediatric patients with achondroplasia (111-901) **Study 6** Randomised, placebo-controlled, double-blind multicentre study to assess the efficacy, safety, tolerability and pharmacokinetics of BMN 111 vs placebo in children from birth to less than 5 years of age with achondroplasia (111-206) **Study 7** Multicentre open-label extension of Study 4 (111-301) to evaluate the long-term safety and efficacy of BMN 111 in children from 5 to less than 18 years of age with achondroplasia (Extension Study 1) **Study 8** Multicentre open-label extension of Study 6 (111-206) to evaluate the long-term safety and efficacy of BMN 111 in children from birth to less than 5 years of age with achondroplasia (Extension Study 2)
Extrapolation, modelling and simulation studies	**Study 9** Extrapolation of efficacy to paediatric subjects from birth to less than 5 years of age with achondroplasia, based on data from paediatric subjects from 5 to less than 18 years of age with achondroplasia (Extrapolation Study 1)
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By February 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of achondroplasia

Authorised indication(s):

- Voxzogo is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing
  - Invented name(s): Voxzogo
  - Authorised pharmaceutical form(s): Powder and solvent for solution for injection
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure